XtalPi Holdings (SEHK:2228) valued after intense trading and growing AI drug discovery fever

XtalPi Holdings (SEHK:2228) gained 7.78% in pre-market trading on the Hong Kong Stock Exchange, drawing attention with heavy trading related to investor interest in the company’s focus on AI-driven drug discovery.

Check out our latest analysis for XtalPi Holdings.

At its latest share price of HK$9.53, XtalPi’s short-term share price return has been mixed, with 90-day decline of 21.11% and 7-day increase of 14.54%. The one-year total shareholder return of 86.50% shows strong long-term momentum and a shift in risk appetite around the AI-driven healthcare story.

If you’re interested in how AI is reshaping public companies beyond XtalPi, it’s a good time to consider 125 Healthcare AI Stocks as potential ideas for further research.

With analyst price targets set near HK$10.26 and HK$9.53 per share, and with both revenue and net profit growing rapidly, you have to ask yourself, is XtalPi still undervalued, or is the market already pricing in future growth?

44.5x preferred price to sales: Is it justified?

XtalPi’s P/S ratio is 44.5x, which is high compared to its direct peers and the Asian life sciences group as a whole.

Because the P/S ratio compares a company’s market value to its annual revenue, a higher number generally indicates that investors are willing to pay more for each unit of sales. For a research platform business with HK$802.6 million in revenue split between drug discovery solutions and AI intelligent solutions for science, such multiples typically reflect strong expectations for the platform’s future growth and commercialization.

Here, the market values ​​XtalPi at approximately 44.5x sales, compared to the peer group average of approximately 6.8x and the broader Asian life sciences industry at approximately 4.9x. That’s a sharp premium. It also far exceeds the estimated fair profit/loss multiple of 11.1x. This provides a reference point from which some investors may focus on where valuations are headed if expectations change.

Check out XtalPi Holdings’ SWS Fair Ratio

Result: 44.5x price-to-sales ratio (overvalued)

However, there are obvious pressure points here that could destabilize sentiment, including a rich P/S multiple of 44.5x and heavy reliance on drug discovery solutions and US revenue.

Learn about the key risks to this XtalPi Holdings story.

next step

With sentiment clearly divided between opportunities and risks, now is the time to see the numbers for yourself and act quickly while opinions are still forming. To weigh both positions in one place, start with two important rewards and one important warning sign.

Looking for more investment ideas?

Don’t limit yourself to a single stock when the tools are built to help you quickly find fresh ideas that fit the way you invest.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.